

NEW PRONTO RECHARGEABLE, VAPOUR RELEASE TECHNOLOGY RECEIVES CE MARK

HIGHLIGHTS:

- **New Pronto™ range of dual action, rechargeable vapour release products have been successfully registered with the European Authority as Class 1 devices and have received a CE Mark.**
- **Pronto™ range comes in two formulation variants - Pronto™ Sleep and Pronto™ Clear - addressing unmet needs in the US\$28bn global sleep aid market* and US\$34bn global nasal congestion, cough, cold and allergy market#.**
- **Both Pronto Sleep and Pronto Clear are now on sale online and Pronto Sleep is now available on shelf in close to 1000 Walgreens stores in the USA.**

July 15th, 2019. Melbourne. Rhinomed (ASX:RNO), a leader in airway technology, and the developers of Mute™, is pleased to confirm that its revolutionary new Pronto™ rechargeable, dual action, vapour release technology has been registered with the European Authority as a Class I medical device. Receiving a CE Mark allows the Pronto range to now be sold throughout the European Union.



The receipt of the CE Mark for the Pronto range follows on from the recent announcement of US FDA approval and Australian TGA approval as a Class 1 device. This is another critical step in ensuring that the Pronto range can be sold globally and will further assist the company in its business development activities.

Revolutionary new Pronto™ technology suite

Based on the company's existing BreatheAssist™ nasal dilator technology (Mute™ and Turbine™), the new Pronto™ OTC range includes the novel Airstream™ release system that allows a continuous release of an essential oil blend into the nasal airstream over a set period of

RHINOMED

MAKE EVERY BREATH COUNT

time. By combining this new vapour release technology with the Mute's stenting action, Rhinomed provides users with a unique dual action device that not only improves nasal airflow but also delivers a soothing blend of pure essential oils traditionally known to help clear a stuffy nose or to help you sleep better naturally.

Pronto also includes a novel recharging and storage case that allows Pronto to be recharged before each use. When Pronto is stored in its case in the recharge position, the Pronto device is replenished with the essential oil formulation so it is ready for use again.

Growing the distribution footprint

The Pronto range is now available online through www.prontosleep.com and www.prontoclear.com, close to 1000 Walgreens stores across the USA and is currently in the process of being listed with Amazon.com in the USA.

The company will be exhibiting at the **2019 NACDS Total Store Expo** in August in Boston, USA where it will showcase its entire technology range. Rhinomed's Mute nasal stent has already established a presence in some 9000 US based drug stores. The company is seeking to expand this footprint and also introduce the new Pronto range to both existing and new retail partners.

The multibillion dollar US sleep and nasal congestion markets continue to represent a significant market opportunity for the company's technology. Further updates on the expanding retail presence will be provided in due course.

For more information about Rhinomed's exciting technology, please visit www.rhinomed.global

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Warrick Lace NWR Communications +61(0) 404 656 408 warrick@nwrcommunications.com.au

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

** Top 6 Things to Know About the \$28 Billion Sleep Market. Market research.com 2019*
Trends in Cough, Cold and Allergy (Hay Fever) Remedies Euromonitor 2015